Weekly paclitaxel in pretreated metastatic breast cancer: Retrospective analysis of 52 patients

Tohoku Journal of Experimental Medicine

Volumn 203, Issue 3, 2004, Pages 205-210

  Baltali, Esmen ^a   Altundag, Kadri ^a,b   Ozisik, Yavuz ^a   Guler, Nilufer ^a   Tekuzman, Gulten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (United States)

Author keywords

Chemotherapy; Metastatic breast cancer; Weekly paclitaxel

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; PACLITAXEL; RANITIDINE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOLERANCE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROPATHY; RETROSPECTIVE STUDY; SOFT TISSUE METASTASIS; STOMATITIS; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 4444264966     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.203.205     Document Type: Article

References (18)

1. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M.R., Viale, G., Giarazzi, R. & Taraboletti, G. (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2, 1843-1849.
2. Bishop, J.F., Dewar, J., Toner, G.C., Smith, J., Tattersall, M.H., Olver, I.N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., Walpole, E., Levi, J., Stephenson, J. & Canetta, R. (1999) Initial paclitaxel improves outcome compared with CMVP combination therapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol., 17, 2355-2364.
3. Ellis, M.J., Hayes, D.F. & Lippman, M.E. (2000) Treatment of metastatic breast cancer, In: Diseases of the Breast, edited by J.R. Harris, M.E. Lippman & M. Morrow, Philadelphia, PA, Lippincott Williams & Wilkins, pp. 749-748.
4. Fossati, R., Confalonieri, C., Torrie, V., Ghislandi, E., Penna, A., Pistotti, V., Tinazzi, A. & Liberati, A. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol., 16,3439-3460.
5. Gori, S., Mosconi, A.M., Basurtol, C., Cherubinil, R., De Angelis, V., Tonato, M. & Colozza, M. (2002) Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori, 88, 470-473.
6. Gasparini, G., Gion, M., Crivellari, D., Morabito, A., Rocco, S., Spada, A., Cognetti, F., Flippelli, G., Silingardi, V. & Amadori, D. (2003) Interim analysis of a randomized phase IIb study of weekly paclitaxel (PCT) with or without trastuzumab (T) as first-line therapy of patients with HER-2/neu positive metastatic breast cancer (MBC): Clinical and biologic results. Proc. Am. Soc. Clin. Oncol., 22, 35, (abstr 138).
7. Luck, H.J. Roche, H. (2002) Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit. Rev. Oncol. Hematol., 44 (Suppl.), 15-30.
8. Manual for Clinical Research in Breast Cancer: EORTC Breast Cancer Cooperative Group (1998) Almere, the Netherlands, Excerpta Medica, 96-97.
9. Milross, C.G., Mason, K.A., Hunter, N.R., Chunk, W.K., Peters, L.J. & Milas, L. (1996) Relationship of mitotic arrest and apoptosis to tumor effect of paclitaxel. J. Natl. Cancer Inst., 88, 1308-1314.
10. Nabholtz, J.M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P. & Winograd, B. (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol., 14, 1858-1867.
11. Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J.G., Gamucci, T., Houston, S., Coleman, R., Schacter, J., Van Vreckem, A., Sylvester, R., Awada, A., Wildiers, J. & Piccart, M. (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol., 18, 724-733.
12. Perez, E.A. (1998) Paclitaxel in breast cancer. Oncologist, 3, 375-389.
13. Perez, E.A., Vogel, A.C., Irwin, D.H., Kirshner, J.J. & Patel, R. (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol., 19, 4216-4223.
14. Seidman, A.D., Hudis, C.A., Albanel, J., Tong, W., Tepler, I., Currie, V., Moynahan, M.E., Theodolou, M., Gollub, M., Baselga, J. & Norton, L. (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J. Clin. Oncol., 16, 3353-3361.
15. Smith, R.E., Brown, A.M., Mamounas, E.P., Anderson S.J., Lembersky, B.C., Atkins, J.H., Shibata, H.R., Baez, L., DeFusco, P.A., Davila, E., Tipping, S.J., Bearden, J.D. & Thirlwell, M.P. (1999) Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer. National Surgical Adjuvant Breast and Bowel Project protocol B-26. J. Clin. Oncol., 17, 3403-3411.
16. Ten Tije, A.J., Smorenburg, C.H., Seynaeve, C., Sparreboom, A., Schothorst, K.L., Kerkhofs, L.G., van Reisen, L.G., Stoter, G., Bontenbal, M. & Verweij, J. (2004) Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicenter phase II trial. Eur. J. Cancer, 40, 352-357.
17. WHO Hand Book for Reporting Results of Cancer Treatment (1999) Geneva, World Health Organization (WHO offset Publication) No. 48, pp.16-27.
18. Wist, E.A., Sommer, H.H., Ostenstad, B., Risberg, T. & Fjaestad, K. (2004) Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol., 43, 11-14.